Thus, our strategy offers an additional advantage over current approaches for oral incretin mimetic peptide delivery and by increasing endogenous GLP-1 levels. All these developments could lead to ...

Semaglutide, as a GLP-1 receptor agonist, works by mimicking incretin ... Food and Drug Administration. Incretin mimetic drugs for type 2 diabetes. Centers for Disease Control and Prevention. Insulin ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

You may soon be able to eat your Ozempic … sort of. GLP-1 supplements are booming, promising to deliver similar benefits to Ozempic and Wegovy without the pricey injections. The latest contender ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Share on Pinterest GLP-1 drugs may protect the brain from inflammation, some studies say, but others warn they may increase depression risk. Image credit: James Manning – PA Images/Getty Images.

Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat obesity. While many drugs in this class are relatively new, researchers ...